Both subtypes are characterized by highly amplified expression of MDM2 and CDK4, making inhibition of these proteins an attractive therapeutic target in the treatment of DDLPS and WDLPS [40, 41]. The gene discussed is CDK4; the disease is dedifferentiated liposarcoma.